Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase.

Bellon S, Parsons JD, Wei Y, Hayakawa K, Swenson LL, Charifson PS, Lippke JA, Aldape R, Gross CH.

Antimicrob Agents Chemother. 2004 May;48(5):1856-64.

2.

Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: A review.

Azam MA, Thathan J, Jubie S.

Bioorg Chem. 2015 Oct;62:41-63. doi: 10.1016/j.bioorg.2015.07.004. Epub 2015 Jul 23. Review.

PMID:
26232660
3.

Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.

Mdluli K, Ma Z.

Infect Disord Drug Targets. 2007 Jun;7(2):159-68. Review.

PMID:
17970226
4.

Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents.

Oblak M, Kotnik M, Solmajer T.

Curr Med Chem. 2007;14(19):2033-47. Review.

PMID:
17691945
5.

Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Donnelly A, Blagg BS.

Curr Med Chem. 2008;15(26):2702-17. Review.

6.

The interaction between coumarin drugs and DNA gyrase.

Maxwell A.

Mol Microbiol. 1993 Aug;9(4):681-6. Review.

PMID:
8231802
7.

[DNA gyrase inhibitor (GyrI) of Escherichia coli].

Nakanishi A, Imajoh-Ohmi S.

Seikagaku. 1999 Jun;71(6):442-8. Review. Japanese. No abstract available.

PMID:
10432838

Supplemental Content

Support Center